Drug Successfully Delays Common Form of Breast Cancer
PD-0332991 lifts Pfizer Inc shares nearly 2 percent.
Dec 5 (Reuters)—An experimental drug showed impressive effectiveness and safety in a mid-stage trial against a common form of advanced breast cancer, lifting Pfizer Inc shares nearly 2 percent.
The favorable results prompted the drugmaker to plan large late-stage trials of the drug next year. If approved, the medicine could fetch multi-billion dollar sales, industry analysts said.
